Cyclopenthiazide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 0.25-0.5 mg/day. Oedema Initial: 0.25-0.5 mg/day. Up to 1 mg/day in patients w/ heart failure.
Dosage Details
Oral
Hypertension
Adult: 0.25-0.5 mg daily alone or in conjunction with other antihypertensives.

Oral
Oedema
Adult: Initial: 0.25-0.5 mg daily, reduce to lowest effective dose for maintenance. Up to 1 mg daily in patients with heart failure.
Contraindications
Severe hepatic or renal impairment; anuria; Addison's disease; hypercalcaemia; porphyria.
Special Precautions
Fluid and electrolyte disturbances; hepatic cirrhosis; gout; DM. Elderly; severe heart failure; renal or hepatic impairment. Monitor blood glucose concentrations in patients on antidiabetics. Pregnancy, lactation.
Adverse Reactions
Electrolyte imbalance; hyperglycaemia; gout; dry mouth; thirst; weakness; muscle pain and cramp; seizures; hypotension; GI disturbances; anorexia; sialadenitis; headache; impotence; yellow vision; hypersensitivity reactions; cholestatic jaundice; pancreatitis; blood dyscrasias; glycosuria; dizziness; photosensitivity reactions, postural hypotension, paraesthesia.
Drug Interactions
Digitalis glycosides; drugs that prolong QT interval; other antihypertensives; competitive muscle relaxants; pressor amines; corticosteroids, corticotrophin; β2-agonists, α-blockers; ACE inhibitors; NSAIDs; alcohol, barbiturates; opioids; lithium; allopurinol; tetracyclines; carbenoxolone; hypoglycaemics.
Action
Description: Cyclopenthiazide reduces the reabsorption of electrolytes from the renal tubules, hence increasing the excretion of Na and chloride ions and consequently of water. It also reduces the glomerular filtration rate.
Onset: 1-3 hr.
Duration: About 12 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cyclopenthiazide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in